Investing.com - Lexicon reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Lexicon announced earnings per...
Lexicon Pharma (LXRX) reported Q4 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $50...
events, and a recording of the webcast will be available for two weeks following the original on-demand date.
NDA for Sotagliflozin Remains on Track for May 2023 PDUFA Date Following Mid-Cycle Review Meeting Final Data from Successful RELIEF-DPN-1 Study of LX9211 in Painful Diabetic...
THE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of...
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
|Average||8.000 (+253.98% Upside)|
|No. of Analysts||2|